Modern approach to neurorehabilitation of children with hiv-encephalopathy

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Background. Currently, there is no standardized and evidence-based medicine specific therapy for HIV-associated neurocognitive disorders.

The aim of the study was to evaluate the effectiveness of various neurorehabilitation programs, including the use of memantine hydrochloride and the virtual reality feedback method (NIRVANA) in children with HIV encephalopathy (HIVE) in the aspect of neurocognitive status.

Material and methods. The study included 260 children with HIV-positive status and receiving highly active antiretroviral therapy (НAART) according to an individually selected scheme for at least 6 months. All the children included in the study showed signs of HIVE. After the initial examination, all patients were divided into 4 groups: only НAART, НAART + memantine, НAART + NIRVANA and НAART + memantine + NIRVANA. The follow-up period was 3 months. The neurological study included a standard neurological examination, as well as various psychometric scales and questionnaires.

Results. In the groups of active neurorehabilitation, there were significant positive changes in the neurocognitive status: the score of all components of neurocognitive disorders decreased in all three groups with comparable relative dynamics. As a result, by the end of the 3rd month of follow-up in children taking memantine (НAART group + M and НAART + M + H) achieved a significantly lower IQ score compared to children who were only on НAART (p <0.001 for both comparisons). Also in children who received complex neurorehabilitation (НAART + M + H) by the end of the 3rd month of observation, a significantly lower integral score of neurocognitive status assessment was achieved compared to children of the НAART group (p <0.05).

Conclusion. Thus, in the course of this study, it was found that children with HIVE, despite the ongoing НAART, have a tendency to progress HIVE. Children with HIV-associated dementia are most susceptible to progression. The use of active neurorehabilitation, especially a combination of memantine and virtual reality techniques, can significantly improve the indicators of neurocognitive status.


Full Text

Restricted Access

About the authors

Saida N. Saidkhodjaeva

Tashkent Pediatric Medical Institute

Author for correspondence.
Email: dr.saida25@gmail.com
ORCID iD: 0000-0002-6317-4476

Uzbekistan, Tashkent

PhD, Associate Professor

Yakutkhon N. Madjidova

Tashkent Pediatric Medical Institute

Email: dr.saida25@gmail.com
ORCID iD: 0000-0002-2464-0315

Uzbekistan, Tashkent

DcS., Professor

Каhramon H. Yuldashev

Tashkent Pediatric Medical Institute

Email: dr.saida25@gmail.com

Uzbekistan, Tashkent

DcS., Professor

References

  1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799. doi: 10.1212/01.WNL.0000287431.88658.8b
  2. Coban H, Robertson K, Smurzynski M, et al. Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressiveregimen. AIDS. 2017;31(11):1565–1571. doi: 10.1097/QAD.0000000000001523
  3. Foca E, Magro P, Motta D, et al. Screening for neurocognitive impairment in HIV-infected individuals at first contact after HIV diagnosis: the experience of a large clinical center in Northern Italy. Int J Mol Sci. 2016;17(4):434. doi: 10.3390/ijms17040434
  4. Wagner GA, Chaillon A, Liu S, et al. HIV-associated neurocognitive disorder is associated with HIV-1 dual infection. AIDS. 2016;30(17):2591–2597. doi: 10.1097/QAD.0000000000001237
  5. Kamal S, Locatelli I, Wandeler G, et al. The presence of human immunodeficiency virus-associated neurocognitive disorders is associated with a lower adherence to combined antiretroviral treatment. Open Forum Infect Dis. 2017;4(2):ofx070. doi: 10.1093/ofid/ofx070
  6. Tsai YT, Chen YC, Hsieh CY, et al. Incidence of neurological disorders among hiv-infected individuals with universal health care in Taiwan from 2000 to 2010. J Acquir Immune Defic Syndr. 2017;75(5):509–516. doi: 10.1097/QAI.0000000000001448
  7. Tsegaw M, Andargie G, Alem G, Tareke M. Screening HIV-associated neurocognitive disorders (HAND) among HIV positive patients attending antiretroviral therapy in South Wollo, Ethiopia. J Psychiatr Res. 2017;85:37–41. doi: 10.1016/j.jpsychires.2016.10.016
  8. Sacktor N, Skolasky RL, Moxley R, et al. Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial. J Neurovirol. 2018;24(1):16–27. doi: 10.1007/s13365-017-0587-z
  9. Ndhlovu LC, Umaki T, Chew GM, et al. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neurovirol. 2014;20(6):571–582. doi: 10.1007/s13365-014-0279-x
  10. Gates TM, Cysique LA, Siefried KJ, et al. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitivedisorder. AIDS. 2016;30(4):591–600. doi: 10.1097/QAD.0000000000000951
  11. Mamik MK, Asahchop EL, Chan WF, et al. Insulin treatment prevents neuroinflammation and neuronal injury with restored neurobehavioral function in models of HIV/AIDS neurodegeneration. J Neurosci. 2016;36(41):10683–10695. doi: 10.1523/JNEUROSCI.1287-16.2016
  12. Gerena Y, Menendez-Delmestre R, Skolasky RL, et al. Soluble insulin receptor as a source of insulin resistance and cognitive impairment in HIV-seropositive women. J Neurovirol. 2015;21(2):113–119. doi: 10.1007/s13365-014-0310-2

Statistics

Views

Abstract - 73

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies